Abdur Rauf1, Seema Patel2, Muhammad Imran3, Aneela Maalik4, Muhammad Umair Arshad5, Farhan Saeed5, Yahia N Mabkhot6, Salim S Al-Showiman6, Nazir Ahmad5, Eman Elsharkawy7. 1. Department of Chemistry, University of Swabi, Anbar-23561, Khyber Pakhtunkhwa, Pakistan. Electronic address: abdurrauf@uoswabi.edu.pk. 2. Bioinformatics and Medical Informatics Research Center, San Diego State University, San Diego 92182, California, USA. 3. University Institute of Diet & Nutritional Sciences, Faculty of Allied and Health Sciences, The University of Lahore-Pakistan. 4. Department of Chemistry, COMSATS University Abbottabad Campus, 22060-Abbottabad, Pakistan. 5. Faculty of Home and Food Sciences, Government College University, Faisalabad, Pakistan. 6. Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 1451, Kingdom of Saudi Arabia. 7. Department of Chemistry, Faculty of Science, Northern Borders University, Saudi Arabia.
Abstract
BACKGROUND: Honokiol ((3',5-di-(2-propenyl)-1,1'-biphenyl-2,2'-diol), a lignan, is a promising antitumor compound, having exerted activity against a number of human cancer cell lines. Honokiol has inhibitory role on the proliferation, invasion and survival of cancer cells in in vitro as well as in vivo studies. It interferes with signaling pathways components in order to elicit the anticancer effect. SCOPE AND APPROACH: In present review, the published data on the efficacy of honokiol against various cancer cell lines and tumor-bearing animal models has been presented and discussed. KEY FINDINGS AND CONCLUSIONS: Honokiol lowers the expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 methyltransferase among numerous other anticancer functions. It increases bone morphogenetic protein 7 (BMP7), Bax protein, among others. It does so by interfering with the major checkpoints such as nuclear factor kappa B (NF-κB), and activator of transcription 3 (STAT3), mammalian target of rapamycin (m-TOR), epidermal growth factor receptor (EGFR), Sonic hedgehog (SHH). It promotes the efficacy of several anticancer drugs and radiation tolerance. The derivatization of honokiol results in compounds with interesting attributes in terms of cancer control. This review will shed light on the scopes and hurdles in the relevance of the bioactive lignan honokiol in cancer management.
BACKGROUND: Honokiol ((3',5-di-(2-propenyl)-1,1'-biphenyl-2,2'-diol), a lignan, is a promising antitumor compound, having exerted activity against a number of human cancer cell lines. Honokiol has inhibitory role on the proliferation, invasion and survival of cancer cells in in vitro as well as in vivo studies. It interferes with signaling pathways components in order to elicit the anticancer effect. SCOPE AND APPROACH: In present review, the published data on the efficacy of honokiol against various cancer cell lines and tumor-bearing animal models has been presented and discussed. KEY FINDINGS AND CONCLUSIONS: Honokiol lowers the expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 methyltransferase among numerous other anticancer functions. It increases bone morphogenetic protein 7 (BMP7), Bax protein, among others. It does so by interfering with the major checkpoints such as nuclear factor kappa B (NF-κB), and activator of transcription 3 (STAT3), mammalian target of rapamycin (m-TOR), epidermal growth factor receptor (EGFR), Sonic hedgehog (SHH). It promotes the efficacy of several anticancer drugs and radiation tolerance. The derivatization of honokiol results in compounds with interesting attributes in terms of cancer control. This review will shed light on the scopes and hurdles in the relevance of the bioactive lignan honokiol in cancer management.
Authors: A Hazafa; M O Iqbal; U Javaid; M B K Tareen; D Amna; A Ramzan; S Piracha; M Naeem Journal: Clin Transl Oncol Date: 2021-10-05 Impact factor: 3.405
Authors: Silvia Lorente-Cebrián; Katya Herrera; Fermín I Milagro; Juana Sánchez; Ana Laura de la Garza; Heriberto Castro Journal: Int J Mol Sci Date: 2019-11-28 Impact factor: 5.923